Neurocrine Biosciences reports preliminary Q4 2021 INGREZZA sales ~$301M, FY ~$1.1B

NEUROCRINE BIOSCIENCES INC

2021-FY EPS reported $0.92 revenue$1,133,500,000

Q4 INGREZZA net sales ~$301M ($296M inventory-adjusted), up 25% YoY; prescriptions up 32% YoY.
Full-year 2021 INGREZZA net sales ~$1.1B.
Full-year 2022 INGREZZA sales guidance to be provided on Feb 11, 2022 earnings call.
Pipeline: sNDA for valbenazine in Huntington chorea in 2H 2022; Phase 2 data for NBI-827104 mid-2022.
Company now has 13 mid-to-late-stage clinical programs with data readouts over the next two years.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.